Fulton Breakefield Broenniman Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$52.8M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$32.7M |
| 3 |
H&R Block
HRB
|
+$19.7M |
| 4 |
Amazon
AMZN
|
+$18.9M |
| 5 |
RTX Corp
RTX
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$3.98M |
| 2 |
Eli Lilly
LLY
|
+$2.54M |
| 3 |
Roper Technologies
ROP
|
+$1.88M |
| 4 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$1.34M |
| 5 |
Johnson & Johnson
JNJ
|
+$597K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.18% |
| 2 | Technology | 16.52% |
| 3 | Healthcare | 12.58% |
| 4 | Financials | 10.5% |
| 5 | Consumer Discretionary | 8.94% |
Similar funds
Fulton Breakefield Broenniman's Q2 2022 Portfolio in Review
As of Q2 2022, Fulton Breakefield Broenniman held 176 positions worth $1.16B, up 1.7% from $1.14B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Fulton Breakefield Broenniman deployed $153M of net new capital in Q2 2022, opening 18 new positions and adding to 47 existing holdings. Its largest new stake was Apple: 348,679 shares worth $47.7M.
By sector, the portfolio is most concentrated in Miscellaneous at 30% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Eli Lilly, an estimated $2.54M trimmed.
- Fulton Breakefield Broenniman's largest Q2 2022 buy was Apple: 348,679 shares worth $47.7M.
- Fulton Breakefield Broenniman added most to Estee Lauder in Q2 2022, an estimated $3.79M increase.
- Fulton Breakefield Broenniman's biggest Q2 2022 reduction was Eli Lilly, cutting an estimated $2.54M.
- Fulton Breakefield Broenniman fully exited Netflix in Q2 2022, selling an estimated $3.98M.
- Fulton Breakefield Broenniman's ten largest holdings make up 30% of its $1.16B portfolio in Q2 2022.
- Fulton Breakefield Broenniman opened 18 new positions and closed 10 in Q2 2022.
- Fulton Breakefield Broenniman's portfolio value rose 1.7% quarter-over-quarter to $1.16B.
Based on Fulton Breakefield Broenniman's 13F filing for Q2 2022, filed 28 Jul 2022.